This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The commercial supply of these products is expected to begin in 2027 and will continue to be supplied till 2032. Under this collaboration, Akums Group will produce and supply multiple SKUs of oral liquid formulations, which the partner company will market across various European countries.
Baldev Bange has become the NPA treasurer, while Mike Hewitson, Dave Thomas and Joanne Wolfe have joined the board until March 2027. Olivier Picard has taken over as the new chair of the National Pharmacy Association (NPA), alongside the organisation's first-ever female vice chair Sukhi Basra.
per cent (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData. The fragile X syndrome (FXS) market across the US and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a CAGR of 31.3
The institution will offer a variety of leadership programmes, ranging from short workshops to extended courses lasting 9 to 12 months, starting in March 2027. SOULs mission is to empower young individuals for roles in public sectors such as health, education, rural development, and sanitation.
15,000 crores and a production tenure from FY 2022- 2023 to FY 2027-28, provides financial incentives to 55 selected applicants for manufacturing of identified products under three categories for six years. The scheme provides financial incentives for the manufacturing of notified products. are manufactured. An incentive amount of Rs.3,215
The Government aims to expand the reach of PMBJP by increasing the number of Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) to 25,000 by March 2027. The post Pharmaceuticals & Medical Devices Bureau of India participates in 43rd Edition of IITF 2024 appeared first on Express Pharma.
per cent from 56,009 in 2023 to 56,163 in 2027. According to GlobalData’s Pharmaceutical Intelligence Center, the diagnosed prevalent cases of CIDP in China are expected to increase at an annual growth rate (AGR) of 0.2
Sales are forecasted to double between 2024 and 2027, as CAR-T therapies continue expanding beyond blood cancers into solid tumours. GlobalData projects 44 new TCI drug approvals by 2029, with 18 expected in 2027 alone.
The current legislative authority for the programs expires at the end of September 2027. The FDA will hold two public meetings in July to discuss reauthorization of its use fee act programs for the fiscal year 2028-2032 period. Continue to STAT+ to read the full story…
Under PMBJP, the government has set a target to open 25000 JAKs by March 31, 2027 across the country. The product basket of PMBJP comprises 2047 drugs and 300 surgical equipment which are sold at retail shops at 50 per cent to 80 per cent cheaper than branded medicines.
Consumers are advised to check for the lot number with an expiration date of September 2027. The company stated that a serious reaction is unlikely, as pharmacies typically repackage the tablets in smaller quantities; however, the appearance of the tablets are similar, with only minor differences in markings and size.
Diabetes medications NovoRapid PumpCart (insulin aspart) 100units/ml solution for injection 1.6ml cartridges is in limited supply until 2027, according to a recent medicines supply notification. In a notice issued by the Department of Health and Social Care (DHSC) on 4 June, it said the medications cannot support new patient initiations.
CMS also proposes launching a drug acquisition cost survey in 2026 that could lead to new drug payment cuts by 2027, 340B Health said in the release. The move is part of the agency’s effort to recoup funds redistributed following a Supreme Court ruling that found CMS unlawfully slashed 340B drug payments between 2018 and 2022.
It is expected that the pre-uniform MPJE will begin to provide scaled score results in 2027. In 2026, the Pre-uniform MPJE will only provide a raw/percentage correct result and will not provide a scaled score result. Read more about the uniform MPJE in this blog post. What are the best practices when taking a practice exam?
With an expected launch in 2027, pemvidutide is forecast to generate sales of $1.21 The fact that VK-2735 may be the first oral GLP-1R to gain approval in obesity presents further commercial opportunities for Viking. Altimmunes pemvidutide is in Phase II for obesity and metabolic dysfunction-associated steatohepatitis (MASH). billion in 2030.
Wockhardt UK Limited has recalled batch number HZ10030 (expiry date: 30/04/2027), distributed in packs of 30 tablets. A batch of Tamoxifen 20mg film-coated tablets has been recalled as a precautionary measure following the identification of a ‘dissolution failure’ during stability testing.
NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191–1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027. This approach balances transparency with administrative feasibility.
billion by 2027. For pharma manufacturers aiming for faster batch release and realtime decision-making, integrating these rapid methods into QC protocols is not just beneficial, it’s becoming the new standard. Market trends and Indian scenario The global market for E. coli and coliform diagnostics is expected to grow at a CAGR of 6.5
This designation reinforces the clinical progress we have achieved for ZL-1310 to-date, and we remain on track to initiate a pivotal study in small cell lung cancer later this year, positioning us for a potential accelerated approval in 2027.
billion by 2027, driven by increasing demand for innovative patient-friendly dosage forms, said Paul Smaltz, Head of the Pharmaceutical Solutions Business Unit at Roquette. The platform provides manufacturers with ready-to-use coating premixes for pharmaceutical prescription, nutraceutical, and over-the-counter (OTC) products.
Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.
The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027. Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research.
Completion Date (Estimated): June 2027 “For people living with advanced ROS1+ lung cancer, who tend to be diagnosed at a younger age, having another treatment option can make a real difference for them and their loved ones,” Janet Freeman-Daily, cofounder and president of The ROS1ders, said in a news release.
The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. The expansion will introduce a new laboratory and advanced machinery such as a new filling line, two large size lyophilisers, a capping machine and an external vial washer.
Data from that trial is expected in 2027. “I Vor is paying RemeGene $45 million upfront along with $80 million in warrants to purchase common stock in exchange for the drug, called telitacicept. Telitacicept is in Phase 3 testing for generalized myasthenia gravis in the U.S., Europe and South America, according to the companies.
The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027.
Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.
The company also has $1 billion in senior notes coming due in 2027. The company believes sales in ambulatory patients are likely to annualize at a minimum of $500 million annually through 2027. Three other “exon-skipping” drugs Sarepta sells for Duchenne could bring in about $900 million per year over that period, the company added.
By 2027, biopharma is projected to account for 35 per cent of the global market, positioning India as a leader. Adam Anderson , Executive VP – Pharma, Informa Markets B.V said, “India’s pharmaceutical sector is stronger than ever, not only in raw ingredients but also in machinery and biopharmaceuticals.
Will he wait until the next PDUFA reauthorization in 2027 to instill additional changes at the agency? Kennedy has been critical of FDAs reliance on user fees to fund its mission. Will Kennedy try to overturn the user fee system thats been in place since 1992?
billion by 2027. Streams, webinars, and other events can serve as a platform to invite other guests and leaders, both from the company and outside of it, to discuss hot topics and industry-related news that your customers and potential clients might be interested in. This means that every second person on the planet will use email services.
CME Review Original Release: June 23, 2025 Date of Most Recent Review: June 23, 2025 Termination Date: Jul 1, 2027 You finished the cast, Now Join EMCrit! This episode’s speaker(s) report no relevant financial relationships with ineligible companies unless listed above. As a member, you can.
Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO’s overall budget for 2026-2027 will be lower than that for 2024-2025. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
The study, which is expected to produce initial results in the first half of 2027, will support potential approval in the US and Europe. By GlobalData Learn more about Strategic Intelligence RemeGen is conducting a global Phase III clinical trial with telitacicept for the treatment of generalised myasthenia gravis.
Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Then the next step is to produce meaningful quantities of these crystals, which will be next year.” After that, it will be about compliance and regulation, as we must ensure that all our processes adhere to pharma regulations.
With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. As of December 2024, the company reported cash reserves of $85.2m.
The hulking factories are tucked away off the roads around the village of Ringaskiddy — operated by the likes of Pfizer, Johnson & Johnson, and BioMarin, whose plant featured signs last week touting a new facility “coming Q1 2027.”
Specialists who detect worsening chronic condition signs early will be rewarded beginning in January 2027 for avoiding hospitalizations, coordinating better with primary care and early intervention. The model encourages tech-enabled patient engagement and will run through December 2031.
The company now expects to end 2027 with $700 million in cash, an increase of $400 million from previous guidance. Biocryst said it will use the proceeds to pay off about $249 million in term debt owed to Pharmakon Advisors , which it said will save $70 million in interest.
Tracking progress and defining success Providence is finalizing short-term goals for 2027 as it tracks progress toward its 2030 vision. “That golden test is the crux of this sort of safety plan for our basket management efforts.”
The company plans to begin the trial next year, with an eye toward regulatory filings in late 2027. Such a medicine, if proven effective, would be the closest thing to a vaccine the HIV field has produced in four decades of research. Read the rest…
Find out more After its strategic review, the company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability. This approach should maintain access to a $600m revolving credit facility while managing liabilities proactively, including repayment of convertible notes due in 2027.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content